NCT Number: NCT00245947
Study Evaluating ERB-041 in Active Crohn's Disease
Evaluate the response of inflammatory serum markers to oral ERB-041 in subjects with inflammation associated with active Crohn's disease.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 1
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Men and women, minimum 18 years of age with a diagnosis of Crohn's disease greater than 3 months,
- Eligible subjects must have adequate hematologic, renal, and hepatic function.
Other inclusions apply
Exclusion criteria
- Use of the following medications within the specified time period before randomization is prohibited:
Within 48 hours before randomization
- Nonsteroidal antiinflammatory drugs (NSAIDs) Within 2 weeks before randomization
- Herbal supplements (except for a daily multivitamin/mineral supplement not containing herbal components).
Other exclusions applies
Treatment and study plan
Primary outcomes
-
Inflammatory serum markers
-
Pharmacogenomics
-
Safety
Secondary outcomes
-
Crohn's Disease Activity Index (CDAI) scores.
-
Cell surface markers
-
Fecal markers
Sponsors and collaborators
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Registry information
Official study title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel- Design, Exploratory Pharmacogenomic, Safety and Activity Study of Orally Administered ERB-041 in Subjects With Inflammation Associated With Active Crohn's Disease
Important dates
- Study start
- 2004
- Primary completion
- 2005
- Study completion
- 2005
- First posted
- Oct 28, 2005
- Registry last updated
- Sep 10, 2009
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases
NCT01988506
Ankylosing Spondylitis, Ankylosis
Créteil, France
View Trial DetailsThe Vitamin D in Pediatric Crohn's Disease
NCT02186275
Crohn Disease, Crohn's Disease
Edmonton, Alberta, Canada
View Trial DetailsThe Effects of Naltrexone on Active Crohn's Disease
NCT00663117
Crohn Disease, Crohn's Disease
Hershey, Pennsylvania, United States
View Trial DetailsMedication Adherence in Patients With Inflammatory Bowel Disease (IBD)
NCT02620514
Colitis, Colitis, Ulcerative
Atlanta, Georgia, United States
View Trial Details